42075-29-6 Usage
Uses
Used in Pharmaceutical Industry:
4-(4-Aminophenyl)-3-methyl-4-oxobutanoic acid is used as an intermediate in the synthesis of novel cardiotonic agents with vasodilator properties. Its unique structure allows for the development of new drugs that can help regulate heart function and improve blood flow, which is particularly important for patients suffering from cardiovascular diseases.
Used in Cardiovascular Applications:
In the field of cardiovascular medicine, 4-(4-Aminophenyl)-3-methyl-4-oxobutanoic acid is used as a key component in the development of new cardiotonic agents. These agents are designed to enhance the strength of heart contractions and promote vasodilation, which can help improve overall cardiovascular health and reduce the risk of heart-related complications.
Used in Drug Synthesis:
As an intermediate in drug synthesis, 4-(4-Aminophenyl)-3-methyl-4-oxobutanoic acid plays a crucial role in the development of new pharmaceutical compounds. Its unique chemical properties make it an attractive candidate for the synthesis of various drugs, including those with potential applications in the treatment of cardiovascular diseases and other medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 42075-29-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 4,2,0,7 and 5 respectively; the second part has 2 digits, 2 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 42075-29:
(7*4)+(6*2)+(5*0)+(4*7)+(3*5)+(2*2)+(1*9)=96
96 % 10 = 6
So 42075-29-6 is a valid CAS Registry Number.
InChI:InChI=1/C11H13NO3/c1-7(6-10(13)14)11(15)8-2-4-9(12)5-3-8/h2-5,7H,6,12H2,1H3,(H,13,14)
42075-29-6Relevant academic research and scientific papers
A 3-methyl-4-oxo-4 - (P-amino) phenyl-butyric acid
-
Paragraph 0059, (2016/12/07)
The invention discloses a preparation method of a levosimendan key intermediate 3-methyl-4-oxo-4-(p-amino)phenylbutyric acid, which comprises six reaction steps disclosed in the specification. The method has the advantages of novel technological design, accessible raw materials, environment-friendly reaction conditions, no need of virulent chemicals, high yield of each reaction step, high total yield and safe and simple operation, and is suitable for industrial production.
Arylalkane, arylalkene and aryl azaalkane, medicaments containing said compounds and method for the production thereof
-
Page/Page column 71-72, (2010/11/27)
The present invention relates to compounds of general formula [in-line-formulae]R—Z1—Z2—Z3—R1, ??(I)[/in-line-formulae] wherein R, R1 and Z1 to Z3 are defined as in claim 1, the tautomers, the diastereomers, the enantiomers, the mixtures thereof and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases, which have valuable pharmacological properties, particularly CGRP-antagonistic properties, pharmaceutical compositions containing these compounds, their use and processes for preparing them.
